Filter Results
Filter Results
Bioconjugates/ADC (1) Mammalian (8) Microbial (1) Parenteral Drug Product (1)
Antibody Drug Conjugates (1) Bispecific Antibody (2) Difficult to Express Proteins (1) Fabs, Fusion, Scaffold and other Recombinant Proteins (1) Monoclonal Antibody (6)
Analytical Development (2) Bispecific DNA-to-IND (3) Cell Line Development (6) Clinical Supply Services (3) Early De-risking & Optimization (1) mAb DNA-to-IND: Ibex® Design (10) Manufacturing: GMP Drug Substance (2)
GS Xceed® Gene Expression System (1) Mammalian Expression Technologies (1)
CDMO Notes Blog post (2) Webinar (on-demand) (3) White paper (5)
mAb DNA-to-IND: Ibex® DesignX
Reset Filters
   Loading...
Showing 1‐10 of 10
CDMO Notes Blog post
6 min read
Accelerated Tox Offerings: A Recipe for Streamlining IND Applications
Accelerating the timeline to tox material can significantly enhance the drug development process, enabling faster IND submissions and providing crucial time savings for toxicology studies.
CDMO Notes Blog post
6 min read
A Faster Path to the Clinic: Accelerating Biologics Development with Integrated Solutions
How Lonza’s team are helping to revolutionise the path to Biologics INDs, with an accelerated approach to drug development
White paper
18 min read
Lonza as Your Lifecycle Partner for End-to-End Bioconjugate Drug Development
Due to the complicated nature of and expense behind developing and manufacturing antibody drug conjugates (ADCs), around 70% of ADC developers rely on the support of contract development and manufacturing organizations (CDMOs). It is, therefore, vital to ...
White paper
10 min read
Large Molecule Manufacturing: Addressing Challenges with Strategies for Success
Large molecule therapeutics have become increasingly prominent, as gene cloning and expression technology made routine production in living cells possible. With innovations in engineering and development technologies responding to the demand for diverse t...
White paper
Lonza Shapes Biotherapeutics Development Programs Around Different CMC Paths
As protein engineering and manufacturing technologies evolve, small biotech and major pharma companies alike need flexible, customized strategies that balance cost, speed and risk to accelerate drug development and approval of biotherapeutics that could a...
White paper
Going From DNA to IND in 11 Months*
Biopharmaceutical companies are under increasing pressure to advance their molecules to first-in-human trials faster than ever before. For drug developers, this is a time-consuming, risky paradigm – on average, just one in every 1,000 of these molec...
Webinar (on-demand)
JAPANESE – Go from DNA to IND in 11 months guaranteed* with Ibex® Design 2.0
The increasing importance of speed to clinic puts pressure on biotherapeutics product development timelines. In this webinar, we discuss how Lonza guarantees* 5 months from DNA to tox drug substance and 11 months to IND with its Ibex® Design 2.0 progr...
Webinar (on-demand)
Go from DNA to IND in 11 months guaranteed* with Ibex® Design 2.0
The increasing importance of speed to clinic puts pressure on biotherapeutics product development timelines. In this webinar, we discuss how Lonza guarantees* 5 months from DNA to tox drug substance and 11 months to IND with its Ibex® Design 2.0 progr...
Webinar (on-demand)
Gene To IND In 12 Months Without Increased Risk
In this webinar we talk about how Lonza’s advanced platform can achieve speed whilst minimizing risks to achieve the optimal program profile for a seamless transition from gene to IND and beyond. To help companies navigate through this uncertainty, ...
White paper
How can you Reduce Timelines from Gene to IND
Accelerating development timelines has always been a focus for the biopharmaceutical industry. Most pharma companies perceive being “first to market” as a major advantage over their competitors, as they anticipate high returns by dominating ma...